“… Key factors | Examples of considerations |
Evidence base | Additional evidence is needed relating to: - Impact of SS on long term breast cancer outcomes e.g. mortality, survival, and over diagnosis [59] , [74]
- Impact of MBD notification without offering further specific care for those with dense breasts [30]
- Clinical and cost-effectiveness of MBD related guidelines within a PB screening programme [54]
|
Resources | Resources to be considered in the context of a screening programme include: - Skilled expertise [62] , [107]
- Screening capacity in terms of workforce, equipment, and software [49] , [59] , [109]
- Workforce planning [62] , [79] , [109]
- Cost to the healthcare system [20] , [49] , [59] , [71] , [73] , [107]
Impact of MBD related guidelines on the HCPs delivering the population-based screening programme in terms of: - Their roles and responsibilities
- The demand on their time [73] , [107]
- The need for additional education and training to provide such a service and to inform and support screening programme participants [30] , [62] , [63] , [64]
|
MBD classification & measurement | Lack of a recommended standardised density measurement tool and criteria for use in a PB screening programme [53] , [54] , [74] , [94] Considerations regarding: - The optimal stage to start measuring breast cancer risk as MBD declines with age and menopause
- The optimal screening interval for screening programme participants with dense breasts and with non-...
|
…”